[Paris, France, 2023 March 3rd]
Today, Cibiltech and The Leeds Teaching Hospitals NHS Trust, represented by Dr Sunil Daga have been announced as winners of the AI Award. This prestigious award is funded by the Accelerated Access Collaborative (AAC), the National Institute for Health Research (NIHR), NHSX and other relevant partners, and applications are assessed through an open competitive process.
The AI Award recognizes outstanding work of companies and organisations that use artificial intelligence to improve health outcomes for patients. Cibiltech's innovative approach to preventing organ failure using AI has been recognized as a game-changer in the medical industry, and the company is thrilled to have been selected as a winner of this prestigious award. This success is due to a collective effort with a special thanks to Charlotte Harden, COO and Deputy Director, NIHR Leeds In Vitro Diagnostic Co-operative, for her help and involvement throughout the process in our application. “We are delighted to support the work of Cibiltech and look forward to seeing real benefits for our patients and the NHS” declares the NIHR Leeds In Vitro Diagnostic Co-operative.
Thanks to the NIHR Grant, the project team will be able to conduct a clinical trial and a health economics study in the UK to prove the efficacy of their cutting-edge technology. This clinical trial represents a crucial step forward in the company's mission to prevent organ failure and improve patient outcomes. “The CIBIL study aims to provide clinical and health economic evidence to allow further deployment of Predigraft in Europe and in the United Kingdom. It opens the way to a large adoption of AI-based medical device software”, states Victoria Hemzacek, Strategic Development Manager of Cibiltech.
“This vital grant will enable testing AI-based medical device software in clinical care in the best possible way with a blinded design. Patients and clinical team are excited to test this in real world and this will pave way for adoption in the NHS with not only predictable power using the computing power but also serve as safety net and reduce risk of harms of delay in action” , states Dr Sunil Daga.
In addition to funding the clinical study, this award will allow us to conduct various activities with patients, patient organisations and clinicians, such as therapeutic content, workshops and other communication tools to improve education around kidney transplantation.
"We are honoured to have been selected as a winner of the AI Award," said Stéphane Hoareau CEO of Cibiltech. "This award is a testament to the hard work and dedication of our team, and we are thrilled to have the opportunity to further our mission of preventing organ failure through the use of AI. We look forward to conducting our clinical trial and continuing to innovate in the field of MedTech."
The AI Award is a significant achievement for Cibiltech and further solidifies their position as a leader in the MedTech industry. The company's commitment to improving patient outcomes through the use of AI is admirable, and we look forward to seeing the results of their clinical trial in the UK.
NIHR official announcement :
About Cibiltech: Cibiltech is a pioneer in the development of artificial intelligence-basedsoftware medical devices, oering solutions to patients, healthcare professionals and thepharmaceutical industry. Cibiltech's ambition is to build the distribution platform foralgorithms to prevent organ failures. Cibiltech's expertise in the regulatory, clinical andinfrastructure aspects of digital health solutions places it in a unique position to achieve thisgoal.
For more information on Cibiltech and their groundbreaking work in preventing organ failure,please visit their website at www.cibiltech.com.